Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent...

Area of Science:

• Biotechnology
• Protein Engineering
• Molecular Biology

Background:

• Affibody molecules are small, engineered proteins derived from Staphylococcal protein A's Z-domain.
• They possess high affinity and specificity for diverse molecular targets.
• Their versatility has led to applications in diagnostics, therapeutics, and biosensing.

Purpose of the Study:

• To review the evolution of affibody constructs from monomers to multivalent assemblies.
• To highlight how this evolution overcomes limitations and expands functionality.
• To discuss recent advances enabling sophisticated affibody-based architectures.

Main Methods:

• Literature review of affibody evolution and applications.
• Analysis of advancements in conjugation chemistry, scaffold engineering, and protein design.
• Examination of multivalent supramolecular assemblies and their properties.

Main Results:

• Monomeric affibodies have been successfully engineered for various targets.
• The transition to multivalent supramolecular assemblies enhances binding avidity and overcomes limitations.
• Recent advances facilitate the creation of complex affibody architectures.

Conclusions:

• Multivalent affibody assemblies represent a significant advancement over monomeric forms.
• Sophisticated affibody architectures improve pharmacokinetic profiles and binding capabilities.
• Affibody-based strategies show great promise in targeted drug delivery, molecular imaging, and theranostics.